Auxly Cannabis Group Inc., a vertically integrated cannabis company operating within the Health Care sector and specifically in the Pharmaceuticals industry, has recently been the subject of financial analysis due to its performance on the Toronto Stock Exchange. As of December 21, 2025, the company’s closing price was CAD 0.15, which is near its 52-week low of CAD 0.03, recorded on December 30, 2024. This low point contrasts with its 52-week high of CAD 0.19, achieved on November 11, 2025, indicating a modest range of volatility in its stock price over the past year.
The company’s market capitalization stands at CAD 202,270,000, reflecting its valuation in the market. Auxly Cannabis Group Inc. trades at a price-to-earnings (P/E) ratio of 4.35, suggesting that its earnings are priced modestly relative to its market value. This P/E ratio is a critical indicator for investors assessing the company’s profitability and growth potential. Additionally, the price-to-book (P/B) ratio is 1.21149, indicating that the market values the company slightly above its book equity. This ratio provides insight into how the market perceives the company’s net asset value.
Auxly Cannabis Group Inc. is known for investing in and supporting cannabis cultivation companies, serving customers globally. The company’s operations are integral to the cannabis industry, which is part of the broader health care sector. Its official website, www.auxly.com , offers further information about its business activities and market presence.
Recently, Auxly Cannabis Group Inc. participated in the Small Cap Growth Virtual Investor Conference on December 9, where it presented its most recent earnings. This event provided investors and stakeholders with insights into the company’s financial health and strategic direction. The presentation highlighted the company’s efforts to navigate the competitive landscape of the cannabis industry and its strategies for growth and sustainability.
Overall, Auxly Cannabis Group Inc.’s financial metrics and recent activities reflect its current position within the market and its potential trajectory in the evolving cannabis sector. Investors and analysts continue to monitor its performance closely, given its role in the health care and pharmaceuticals industries.
